Press Releases
May 30, 2025
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
May 27, 2025
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
May 6, 2025
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
April 27, 2025
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
April 23, 2025
NurExone Appoints Biotech Industry Leader – Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
April 10, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 4, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
March 16, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
February 16, 2025